CDC to Hold Emergency Meeting to Discuss Incidents of Heart Inflammation in Young People After Receiving COVID-19 Vaccine


Pfizer / BioNTech say they could upgrade their vaccine if needed (AFP)

The CDC Advisory Committee on Immunization Practices will hold an emergency meeting on June 18 to discuss a potential link between heart inflammation and COVID-19 mRNA vaccines.

In accordance with Becker’s Hospital Review, in a June 10 presentation to the FDA advisory committee, the CDC said it had received 275 cases of myocarditis, inflammation of the heart muscle or pericarditis, inflammation of the lining of the heart muscle, in people between the ages of 16 and 24 after receiving his second dose of the Pfizer or Modern COVID-19 vaccine.

The CDC advisory group said the number of cases is more than 10 to 102 cases of the conditions scientists had predicted in this age group. “We clearly have an imbalance here,” said Tom Shimabukuro, MD, who works at the CDC’s Office of Immune Safety, during the June 10 meeting.

The CDC revealed Thursday that the agency has received a total of 475 cases of myocarditis and pericarditis in people under 30, according to The hill, although preliminary data suggest that the vast majority of these patients had fully recovered from symptoms.

Dr. Shimabukuro noted that not all reported cases can be real cases. “It’s a bit of a comparison between apples and oranges because, again, these are preliminary reports. Not all of these will turn out to be true reports of myocarditis or pericarditis. ”

Shimabukuro also said the cases are consistent with reports of rare cases of heart inflammation that had been studied in Israel and was reported from the U.S. Department of Defense earlier this year.

“Risk-benefit considerations for determining whether an emergency use authorization should be issued for the use of a COVID-19 vaccine in healthy pediatric individuals should take this information into account, and the risk-benefit consideration it will be different, not only compared to adults, but they may also be different for younger pediatric groups than for older ones, ”said Dr. Marion Gruber, director of the FDA’s immunization office, at the meeting. .

Advertising. Scroll to continue reading.

Source link